{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002428378,0.002235773,0.002892884,0.0004834323,0.0004951491,0.001335595,0.001430555,0.001848342,0.006859031],"category_scores_gemma":[0.001607354,0.0009342381,0.00170538,0.000466582,0.001561766,0.001270771,0.000507238,0.003640113,0.001483547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001258262,"about_ca_system_score_gemma":0.001976916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001331439,"about_ca_topic_score_gemma":0.003227825,"domain_scores_codex":[0.9992658,0.0003821921,0.00003017065,0.0001125209,0.00004952799,0.0001597574],"domain_scores_gemma":[0.9986972,0.0002557101,0.0002538218,0.00008439728,0.00006237206,0.0006465008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9613875,0.02162507,0.0006759585,0.0002669716,0.000412887,0.00003374549,0.00005152221,0.0003909007,0.003636,0.0001208763,0.0007955839,0.01060288],"study_design_scores_gemma":[0.8735855,0.1235989,0.001022499,0.00001396465,0.0002265979,0.00003148294,0.00002268839,0.0003922464,0.0004529009,0.00009700029,0.0005443131,0.00001191672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863384,0.001975231,0.0006245662,0.0008303358,0.0005906888,0.005968989,0.001448901,0.0001246909,0.002098236],"genre_scores_gemma":[0.9783571,0.002138917,0.002173804,0.00200752,0.000572711,0.007691466,0.002015121,0.00003932555,0.005003976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006859031,"threshold_uncertainty_score":0.02294576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03195292858781053,"score_gpt":0.4375393702416746,"score_spread":0.405586441653864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}